Clinical Trials – Page 27

Caplyta Achieves Significant Victory in Major Depressive Disorder Trial, Paving Way for Competition with Vraylar

1 year ago talkbio0Tagged AbbVie, adjunctive therapy, Antipsychotic Agents, Approved, Caplyta, Clinical Trials, Depressive disorder, Intra-Cellular Therapies, Lumateperone, Major Depressive Disorder, United States Food and Drug Administration, Vraylar

Caplyta, lumateperone, Intra-Cellular Therapies, major depressive disorder, MDD, Vraylar, AbbVie, antipsychotic, adjunctive therapy, FDA approval, clinical trials

Aerovate Therapeutics’ Shares Plummet 93.3% After Disappointing IMPAHCT Study Results for AV-101 in Pulmonary Arterial Hypertension

1 year ago talkbio0Tagged 4-aminohippuric acid, Aerovate, AV-101, Biotech Stocks, Clinical Trials, Drug Formulation Process, imatinib, IMPAHCT, Inspiration function, Pulmonary arterial hypertension

Aerovate Therapeutics, AV-101, IMPAHCT Study, Pulmonary Arterial Hypertension, PAH, Imatinib, Inhaled Formulation, Biotech Stocks, Clinical Trials

Gilead’s Magrolimab Ineffective, Linked to Increased Risk of Death in MDS Patients

1 year ago talkbio0Tagged Clinical Trials, concerns, Gilead, magrolimab, Malignant Neoplasms, Miller Dieker syndrome, MYELODYSPLASTIC SYNDROME, Safety

Gilead, Magrolimab, MDS, Myelodysplastic Syndrome, Cancer Treatment, Clinical Trials, Safety Concerns

Revolutionizing Clinical Trials: Leveraging AI for Enhanced Efficiency and Accuracy

1 year ago talkbio0Tagged Accurate (qualifier), AI-Powered Tools, Artificial Intelligence, Auditory recruitment, Clinical Trials, Data Analysis, Efficiency, Precision Medicine

Artificial Intelligence, Clinical Trials, Data Analysis, Patient Recruitment, Personalized Medicine, AI-Powered Tools, Medical Research, Efficiency, Accuracy

Huntington’s Disease Clinical Trials: Updates on Dalzanemdor and Tominersen

1 year ago talkbio0Tagged Clinical Trials, dalzanemdor, Huntington 's disease, Impaired cognition, NMDA receptor modulator, Phase 2, Phase 3 studies, RNA-based therapy, tominersen

Huntington’s disease, clinical trials, dalzanemdor, tominersen, cognitive impairment, RNA-based therapy, NMDA receptor modulator, Phase 2 and Phase 3 studies